Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

mycobacteria, tuberculosis
Mo.A. 140, No.8. 1209, Mo.B. I1295,
Mo.B. I1310, Mo.B. 1358, Mo.B. 1365,
Mo.B. I367, No.B. 1368, No.8. 1373,
Mo.C. I1640, No.C. 1642, No.C. 1643,
Mo.C. I1644, MoC. 1646, NoC. 1647,
MoC. 1648, NoC. 1651, Mo.C. 1655,
Mo.C. I1660, MoC. I1661, Pub.B. 1036,
Pub.B. I1069, Pub.B. I109 1, PubB. 1092,
Pob.B. I1093, Pub.B. 1094, Th.A.395,
Th.A.4065, Th.B.4286, Th.B.4302,
Th.B.4306, Th.B.4307, Th.B.4308,
Th.B.43 I 0,Th.C.330,Th.C.33 I,Th.C.333,
Th.C.334,Tu.B.23 I 9,Tu.B.2354,Tu.B.2355,
Tu.B.2358,Tu.B.2359,Tu.B.2360,
-Tu.B.236 I,Tu.B.2367,Tu.B.2368,
Tu.C.2625,Tu.C.2656, We.A.3059,
We.B.302, We.B.304, We.B.305,
We.B.306, We.B.3246, We.B.3268,
We.B.3352, We.B.3353, We.B.3354,
We.B.3355, We.8.3357, We.8.3358,
We.C.34 I17, We.D.3662, We.D.38 IS
mycoplasma
Tu..2212
myeloid growth factor therapy
Mo.B.1287
myelosuppression
We.B.3222
myocarditis
No.8.1270, No.8.1271, No.8.1395
myopathy
No.8.1273, Mo.B. 1300
N-glycosylation
MoC. I 458,Tu.A. 141, We.B.30 I
NAC
Th.B.4096, Tu.A.2002, Tu.A.2032
national AIDS programs, SEE public
policy
Mo.B. 1314, MoC. 1652, MoD. 1762,
Mo.D. 18 19, Mo.D. I1820, Pub.D. 1409,
Th.C.4372, Th.C.4544, Th.C.4787,
Th.C.4806,Th.C.4837,Th.D.236,
Th.D.4944,Th.D.499 I,Th.D.5025,
Th.D.520 I,Tu.D.2760,Tu.D.475,
We.C.58 I, We.D.3675, We.D.3745,
We.D.3892
national policy, SEE public policy
Th.C.4788, Th.C.4789, Th.C.4836,
Th. D.4994, Th. D.4997, Th. D.5002,
Tu.8.2 I158, Tu.C.2 I10, Tu.D2936, Tu.D.486,
We.C.3574, We.D.230, We.D.232,
We.D.234, We.D.367 I
native people, SEE aboriginal people
Mo.D. 19 16, Mo.D. 191 8, Mo.D.482,
Pub.D. I1362, Th.C.4470, Th.C.4799,
T h. D.4906, Th. D.5 I128, Tu. C.2620,
We.D.3798
natural cytotoxicity
Tu.A.2004, We.A.3069
natural history, SEE progression
No.8.1222, No.8.1269, No.8.1335,
No.8. I1379, Mo.C. 1535, Ma.C. 1665,
Mo.C.322, Pub.B. I063, Th.C. I25,
Tu.A. I16 I,Tu.A.2008,TuB. I 76,Tu.B.2236,
Tu.B.2237, Tu.B.2256,Tu.B.3 I13, We.A.503,
We.B.3247, We.8.325 I, We.B.3253,
We.8.3254, We.8.3333, We.B.3335,

needle sticks, SEE health care
personnel, risks to
Pub.C. I I83,Tu.B.2259
needle-syringe exchange, SEE IDUs
Mo.D.1802, Mo.D.243, Mo.D.36 1,
Mo.D.362,Th.C.4634,Tu.C.2529,
We.C.35 I15, We.C.3536, We.C.3552,
We.C.356 I, We.D.235
Nef gene
Mo.A. 1033, Mo.A. 104 I,Th.A. 147,
Th.A.384,Tu.A.2033,Tu.A.2063,
We.A.302 I
Neisseria gonorrhea
Mo.C.34 I, Mo.C.440, Pub.C. 1286,
Th. B.4 I166, Th.C.474 I, Tu. B.2 145,
We.A.5 10
neonates, SEE children
Th.B.4325,Tu.C.2572
neoplasms
No.8.1265, Mo.B. I1302, Mo.B. 1309,
Pub.8. 1047, Pub.B. I 062,Th.A.275,
Th.A.4079,Th.B.4 I 38,Th.B.4 141,
Th.8.4235,Th.B.4289, We.C.3430
neopterin
No.8. I1338, MoC. 1573, Pub.A. 1026,
Th.8.4295,Th.B.4325,Th.C.224,
We.B.3350, We.C.3394
nervous system
No.8.1231, No.8.1290, No.8. 1301,
Th.A.4069, Tu.A.2076, Tu.B.2260,
Tu.8.226 I,Tu.B.2262,Tu.B.2265,
Tu.B.2278, We.A.3095, We.B.3290,
We.8.3295
neuropathy, peripheral
No.B. 1283, No.8. 1305, No.8. 1356,
Th.8. I180, Th. B.425 8, Tu. B.226 I, Tu. B.2262,
We.B.3288, We.B.3362
neuropsychological impairment
No.8.1336, No.B.3 I13,No.D. 1877,
No.D. I1886, Th.B. I180, Th.B.4259,
Tu.A.20 I18, Tu.B.2265, Tu.B.2269,
We.B.3284, We.8.3289, We.C.3442
neuropsychology
No.B. I1336, No.B.3 I13, No.D. 1893,
No.D. I1894, Th. B.4257, Th. B.4259,
Th.D.5 I 67,Tu.B. I 74,Tu.8.2263,Tu.B.2269
neurosyphilis
Th.8B.4 I170, Th.B8.4260
neurotropin
We.8.3284
neutralisation epitopes
No.A.270, No.A.27 I, No.A.274,
Tu.A.2062, Tu.A.2082, Tu.C.2588
neucralising antibodies
No.A.270, No.A.27 I, No.A.273,
No.A.283, No.A.284, No.8. 1177,
Pub.A. 101 I, Tu.A.2007, Tu.A.20 I 1,
Tu.A.2047, Tu.A.2088, Tu.A.2098,
Tu.A.2099, Tu.A.5 I12, Tu.C.2588,
We.A.284, We.A.30 14, We.8,3328,
We.8.3372, We.B.3377, We.8.3378,
We.8.3379, We.C.460
neutralising monoclonal antibodies
No.A. 1003, No.A.274
neutropenia
No.8. I1285, Th.C.223, Tu.B. I180, Tu.B.2 I159,
Tu.8.2284,Tu.B.2307, We.A.3094,

Mo.A. 1077, No.8. 1123, No.B. 1125,
No.8. 1326, Pub.A. I 002,Tu.B.2324,

Tu.B.2325,Tu.B.2326,Tu.B.2327,
We.A.520, We.B.3 I1I6, We.B.3 131,
We.B.3 I132, We.B.3 136
non-progressors, long term, SEE also
survivors, long term
No.A. 1033, No.A.390, Mo.A.393,
MNo.8B.1257, MNo.8B.1259, MNo.8B.1260,
No.8.1260, No.8.1261, No.C.323,
No.D. 1880, No.D. 1880, No.D. 1885,
No.D. I1885, Pub.C. I1I54, Th.A.4034,
Th.A.404 I,Th.B. I 73,Th.D.5095,
Th. D.5 I154, Th. D.5 15 8, Tu.A.2005,
Tu.A.20 I14, Tu.A.20 I14, Tu.A.2028,
Tu.A.2028, Tu.A.2046, Tu.A.2088,
Tu.A.28 I,Tu.A.28 I,Tu.A.392,Tu.A.393,
Tu.A.5 I13, Tu,..I90, Tu.B. I195, Tu.B.2309,
Tu.B.3 I 3,Tu.B.3 I 3,Tu.C.2520,Tu.C.2567,
Tu.C.2567,Tu.C.434,Tu.C.550,Tu.C.55 I,
Tu.C.552,Tu.C.553,Tu.C.553, WeA. I141,
We.A.30 I15, We.A,305 I, We.B.3 133,
We.B.3 I3 3, We.B.3324, We.B.3327,
We.B.3327, We.B.338 I, We.C.343 I,
We.C.3457, We.C.3457, We. C. 3463,
We.C.3463, We.C.3464, We. C. 3465,
WeC.3465, We.C.3466, We.C.3467,
We.C.3467, We.C.3469, We.C.3470,
We.C.34/ I, We.C.3472, We.C.3473,
We.C,3474, We.C.3475, We.C.34 /5,
We.C.347 7
non-syncytium-inducing variant
(NSI variant)
Tu.A.2047,Tu.A.206 I,Tu.A.2073,
Tu.B.2238,Tu.C.2567
nongovernmental organisations (NGO)
No.D. 137, MoD. 1697, No.D. 1764,
No.D.1813, No.D.1833, Mo.D.1920,
No.D,1922, Pub.C. I1108, Pub.C. I1272,
Pub.D. I1338, Pub.D. I340, Pub.D. 1345,
Pub.D.1356, Pub.D.1360, Pub.D.1361,
Pub.D.1400, Pub.D.1409, Pub.D.1455,
Pub.D.146I, Pub.D.1473, Pub.D.1475,
Th.B.4 I 02,Th.B.4 I1I 3,Th.B.424 I,
Th.C.2 I12, Th.C.44 I15, Th.C.4473,
Th.C.45 I16, Th.C.4545, Th.C.4653,
Th.C.4654,Th.C.4742,Th.C.476 I,
Th.C.4762, Th.C.4768, Th.C.4799,
Th.C.4840, Th.C.4857, Th.D. 13 1,
Th.D. I 35,Th.D.450,Th.D.4989,
Th.D.499 I,Th.D.499 I,Th.D.4993,
Th.D.500 I,Th.D.503 I,Th.D.5042,
Th. D.5049, Th. D.5 I1I8, Th. D.5 131,
Th.D.5 I 35,Th.D.5200,Tu.C.267 I,
Tu.C.33 I,Tu.D.236,Tu.D.27 I 5,Tu.D.2736,
Tu. D.2784, Tu. D.2849, Tu. D.2872,
Tu.D.2877,Tu.D.2887,Tu.D.2927,
Tu.D.2944,Tu.D.485,Tu.D.486,
We.C.3580, We.D.3622, We.D.3627,
We.D.3672, We.D.3675, We.D.3699,
We.D.3700, We.D.3745, We.D.3755,
We.D.3777, We.D.3806, We.D.3839,
We.D.3853, We.D.3855, We.D.3862,
We.D.3885, We.D3887, We.D.3889,
We.D.3893, We.D.3894, We.D.3898,
We.D.3899, We.D.3900, We.D.39 12
nonoxynol-9
Mo.A.1053, Pub.C.I 1 19, Pub.D. 1342,
Th.C.320,Th.C.32 I,Th.C.323,Th.C.324,

nurses, SEE health care personnel
No.8. 1166, No.8.190, No.8.SS3,
Pub.8.1034, Pub.8.1038, Pub.C.l1141,
Th.C.4553, Th.C.4554, Th.C.4555,
Th.C.4676, We.D.3765, We.D.3907
nutrition
No.B. 1164, No.8. 1382, No.8. 1385,
No.8.1387, No.8. 1388, No.8.1389,
No.8.1390, No.8. 1393, No.8.1396,
No,8.30 I, No.8,42 1, No.8.422,
No.8.423, Mo.C. 1595, Mo.C.320.
Pub.B. I1098, Pub.D. I 478, Th.B.4 I128,
Th.8.4237,Th.B.4238,Th.8.4239,
Th.B.4240,Th.8.4243,Th.B.4244,
Th.8B.4245, Th. B.4246, Th. 8.4247,
Th. B.4248, Th. B.4249, Th. B.4250,
Th.B.425 I,Th.B.4254,Th.8.427 I,
Th.8.432 I,Th.C.4562,Tu.8.2247,
Tu. B.2248, Tu. B.2249, Tu.8B.2275,
Tu.B.2286,Tu.B.23 I 2,Tu,8.23 I16,
Tu.B.2379,TuB.238 I,Tu.B.2382,
Tu.B.2384, We.B. I18 I, We.B. I182,
We.B. I183, We.B. I185, We.8. I186,
We.8.3257, We.8.3258, We.8.3259,
We.8.3260, We.8.3261,We.8.3262,
We.B.3263, We.8.3264, We.8.3265,
We.8.3266, We.8.3267, We.8.3269,
We.B.327 I, We.B.3273, We.8.3309,
We.B.3362, We.C.34 I19, We.C.3420,
We.C.34 /4
nutritional support
No.8.13 IS, No.8.302, MoC. 1595,
Mo.D.1748, Pub.B. I 064,Th.A.4064,
Th.B. I 82,Th.B.4239,Th.B.424 I,
Th. B.4242, Th.8B.4245, Tu. B.2246,
Tu.8.2248,Tu.B.2347,Tu.C.2448,
We.B. I186, We.B.3260, We.B.3269,
We.8.3273, We.8.3293
occupational therapy
No.8.1 157, No.8. I 164, Pub.D. 1482,
We.B.3263
occupational transmission
No.8.SS2, Th.C.4568, Tu.8.2259,
Tu.C. I120, Tu.C. 1I,22,Tu.C. I123, Tu.C.2609,
Tu.C.26 I 0,Tu.C.2643, We.D.3626
occupational transmission, case reports
Pub.C. I1141,Th.C.4808
occupational transmission, exposure to
pathogens
Mo.C. 1647, Pub.C. I1I38, Tu.C. 121,
Tu.C.123
occupational transmission, magnitude
of risk
No.C.335, Pub.C. I I83,TuC. I120,
TuC. I123, Tu.C.269 I, Tu.D.2766
occupational transmission, management
of exposure
No.C.335,Tu.C. I 20,Tu.C. 122,
We.C.360 I
occupational transmission, prevention
Pub.C. 1 106, Pub.C. 1 140, Pub.D. 1435,
Th. D.374, Tu.C. 121,Tu.C. I122, Tu.C. 123,
Tu.C. I24, Tu.C. I125, Tu.C.2670,
We.C.3600, We.C.360 I, We.C.3602,
We.D.3744
occupational transmission, route of
transmission

No.8.1 14, No.8.121S, No.8.1217,
No.8. 1243, No.8. I1262, No.8. 1266,

I'
D\
0
U
C
C
0
U
C
0
0
C

492